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To determine whether impaired diastolic function may
be an early sign of doxorubicin cardiotoxicity, a retro-
spective study was performed in 12 patients who had
undergone serial radionuclide angiography and were
found to have a left ventricular ejection fraction of 55%
or more before doxorubicin (Adriamycin) treatment and
during follow-up. Average rapid filling velocityand slow
filling velocity were both significantly reduced after dox-
orubicin treatment. Rapid fillingvelocitydecreased from
5.17 ± 1.52 to 4.18 ± 0.96 units/s (p < 0.01), and slow
filling velocity decreased from 2.20 ± 1.32 to 1.42 ±
0.62 units/s (p < 0.05). There were no significant changes
Doxorubicin (Adriamycin) is an anthracycline antibiotic agent
that is effective in the treatment of various solid tumors and
hematologic malignancies (1,2). Owing to its dose-related
cardiac toxicity (3,4), the usefulness of this drug is limited
to treatment durations of usually less than I year, and re-
sponders may require discontinuation of effective treatment.
Although clinical congestive heart failure occurs in up to
one-third of patients receiving a total dose of more than 550
mg/rn? body surface area (3,4), patients may develop heart
failure at a lower total dose (1,5-7) . Consequently, clini-
cally sensitive tests are needed to select patients in whom
treatment must be stopped early .
Various techniques have been used for early detection of
subclinical doxorubicin-induced cardiomyopathy, including
electrocardiography (8,9), systolic time intervals (10, II),
echocardiography (12-14) , radionuclide angiography
(6,7,15-17) and endomyocardial biopsy (17-19). Most studies
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in filling volume ratio, total diastolic time or diastolic
time ratio .
Because a change in left ventricular diastolic function
can occur before ejection fraction falls to subnormal
levels,diastolic function as wellas systolicfunction should
be examined for the early detection of doxorubicin car-
diotoxicity. The clinical implications of our observations
can only be established by a longer-term prospective
analysis of left ventricular function in patients receiving
doxorubicin therapy.
(1 Am Coil CardioI1987;9:184-8)
of doxorubicin cardiotoxicity have dealt with systolic func-
tion of the left ventricle , and effects on diastolic function
have not been reported. The purpose of this study was to
evaluate whether doxorubicin can alter left ventricular di-
astolic function before changes in systolic function are ev-
ident.
Methods
Patient selection. Because of the retrospective nature
of this study, this protocol was designated as exempted
research by the Human Research Committee. Records were
reviewed of all patients who had radionuclide angiography
both before and after doxorubicin therapy between January
1982 and February 1985 at the Medical College of Ohio
Hospital. Those patients were selected for study who had
left ventricular ejection fractions of 55% or more by radio-
nuclide angiography both before the first dose of doxoru-
bicin and during the follow-up period; there were 12 such
patients.
All patients except one were female . Ages ranged from
16 to 69 years (mean 53.3) . Five patients had ovarian cancer
and of the remaining seven patients, one each had endo-
metrial cancer, cervical cancer, carcinoid tumor, Hodgkin 's
lymphoma, Ewing's sarcoma, breast cancer and leiomyo-
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Figure 1. Left ventricular time-activity curve. A = start of rapid
filling; B = end of rapid filling; C = start of slow filling; D =
end of slow filling. Rapid filling time = A to B. slow filling
time = C to D and total diastolic time = A to D.
sarcoma, No patient had a history of mediastinal irradiation.
Two had hypertension.
Drug administration. Patients received doxorubicin in
doses ranging from 80 to 448 rng/nr' body surface area
(mean 193 ± 102). Most patients received the drug as a
single bolus intravenous injection every 3 to 4 weeks. One
patient received doxorubicin for 4 consecutive days every
4 weeks. All patients except one were given doxorubicin in
combination with cyclophosphamide, cis-platin, vinblastine
or thio-TEPA. No patient developed clinical evidence of
heart failure,
Protocol. Two multigated radionuclideangiograms were
reviewed for each patient. The first was obtained before
doxorubicin therapy was initiated; the second was obtained
after the course of doxorubicin therapy was completed, The
mean interval from the first dose of doxorubicin to the sec-
ond radionuclide angiogram was 110days (range 72 to 241)
and from the last dose of doxorubicin to the second study
was 27 days (range 7 to 43).
Radionuclide angiography. The study was performed
with patients in the supine position using red blood cells
tagged with 20 mCi of technetium-99m pyrophosphate(20).
Counts were acquired in the left anterioroblique view show-
ing best separation of right and left ventricles. using a
Technicare Sigma 120 portable gamma camera, equipped
with a GAP collimator and interfaced to a Technicare MCS
560 portable computer. Electrocardiographic-gated images
were used to collect data into 16 frames, each frame having
a duration of 1/1 6th of the RR interval, and an average left
ventricular count value of 125 counts/pixel . Data were stored
on floppy disks in a 64 X 64 matrix with a pixel size of
2.4 mm. After completion of imaging. time-activity curves
and left ventricular ejection fraction were computed using
Technicare software. The ejection fraction was calculated
by subtracting the left ventricular end-systolic counts from
end-diastolic counts, and dividing the result by left ven-
tricular end-diastolic counts,
Diastolic function variables. Diastolic function curves
were examined in a manner similar to that of Smith et al.
(21). Several measurements were calculated from the time-
activity curve (Fig. I). Four diastolic points were marked
by the operator, indicating I) start of rapid filling, 2) end
of rapid filling, 3) start of slow filling, and 4) end of slow
filling . From counts and time at these points, the following
variables were calculated:
Rapid fi lling velocity and slow filling velocity, A regres-
sion line was plotted for counts versus time between start
Table 1. Variables Before and After Doxorubicin Therapy in 12 Patients
Pre-DXR Post-DXR p Value
Heart rate (beats/min) llll :': 15 11 2 ± 12 NS
Blood pressure (mm Hg)
Systolic 124 ± 21 122 :': I II NS
Diastolic 76 ± 9 78 ± 10 NS
Systolic functi on
EF (%) 64 ± 6 61 ± 7 NS
Diastol ic function
RFV (units!s) 5.17 ± 1.52 4. \8 ± 0.96 < 0.0 \
SFV (units!s) 2.20 ± 1.32 1.42 ± 0.62 < 0.05
FYR 0.61 :': 0 .16 n.71 :': 0 .14 NS
RFr (ms) 12Ull ± 37.51 14R.97 ± 50.95 NS
TOT (ms) 255,87 ± 81.63 271.02 ± 17.73 NS
OTR 0.50 ± 0. 13 n.55 ± 0.15 NS
Values are ± SO . DTR = diastolic time ratio ; DXR = doxorubicin; EF = ejection fraction ; FVR
filling volume ratio ; RFr = rapid filling time; RFV = rapid tilling velocity; SFV = slow filling ve locity;
TOT = total diastolic lime .
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and end of rapid filling and between start and end of slow
filling. Average rapid and slow filling velocities were taken
as the slopes of these regression lines in counts per second
divided by the end-diastolic counts and expressed as
units/second.
Filling volume ratio. The ratio of rapid filling volume to
rapid plus slow filling volume was defined as: filling volume
ratio = (counts at ERF - SRF)/(counts at ESF - SRF),
ERF and SRF = end and start , respectively, of rapid filling.
Rapid filling time. total diastolic time and diastolic 'time
ratio . The duration of rapid and slow filling times and the
ratio of rapid filling time to total diastolic time (diastolic
time ratio) were also calculated from the points marked on
the time-activity curve .
Statistics. Statistical comparisons were made by the paired
t test. Correlations were performed using Pearson's corre-
lation coefficient.
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Figure 3 . Slow filling velocity before and after doxorubicin
therapy in 12 patients.
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was also a significant reduction in average slow filling ve-
locity (p < 0 .05) (Table I , Fig. 3). Rapid filling time was
insignificantly prolonged . There were no significant changes
in diastolic filling volume ratio, total diastolic time and
diastolic time ratio after doxorubicin. No correlation was
found between the cumulative doxorubicin dose and changes
in diastolic variables.
Discussion
The clinical syndrome of doxorubicin-induced cardio-
myopathy is related to the total dose administered (3,4) .
Because of this dose-related cardiotoxicity, 'early inappro-
priate discontinuation of doxorubicin therapy may minimize
its therapeutic efficacy in many patients. Previous attempts
designed to predict the presence of subclinical doxorubicin
cardiomyopathy by noninvasive assessment of left ventric-
ular systolic function have been reported (6-18) but have
not resulted in establishment of a sensitive means of early
detection .
Diastolic dysfunction. Myocardial contraction and re-
laxation are loosely coupled processes that may be ' sepa-
rately influenced by certain stimuli (22). Diastolic impair-
ment may therefore occur in the absence of systolic dysfunction
and may develop coincident with or even before abnor-
malities of systolic performance (23,24). Reports of the
occurrence of diastolic dysfunction with little or no systolic
impairment in various heart diseases such as coronary artery
disease (25-27), volume overload and pressure overload
states (28-30) and cardiomyopathy (31) led us to investigate
this phenomenon in patients who received doxorubicin and
who maintained a normal ejection ' fraction . The present
study suggests that gated radionuclide angiography can be
used to detect doxorubicin-induced diastolic dysfunction be-
fore there is evidence of systo lic dysfunction or clinical
evidence of cardiotoxicity.
After
P< .Ol
Before
2.01 _
Ejection fraction. Heart rate and blood pressure were
not significantly changed from pretreatment values after
doxorubicin therapy. There was no significant decrease in
left ventricular ejection fraction after doxorubicin, ejection
fraction remaining greater than 55% before and after dox-
orubicin therapy as expected by selection criteria for these
12 patients (Table I).
Average rapid left ventricular filling velocity showed a
significant decrease after doxorubicin therapy (p < 0.0 I)
(Table I, Fig . 2) . No significant correlation was found be-
tween the change in average rapid filling velocity and the
changein ejection fraction (r = 0.43, P > 0.05). There
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Figure t . Rapid filling velocity before and after doxorubicin
therapy in 12 patients.
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Of the six variables of diastolic function tested. only two
showed significant changes: rapid and slow filli ng velocity.
The change in average rapid fi lling velocity was more sig-
nificant than the change in slow fill ing velocity. We em-
ployed average filling velocities as measures of diastolic
function. Although previous studies (25,26,29) have used
the peak rate of filling as an indication of diastolic function,
that measurement is extremely dependent on tine temporal
resolution. Although average fill ing velocities are less sen-
sitive to noise, they are not independent of temporal reso-
lution. We attempted to minimize heart rate variability by
setting a gate for each patient to reject beats with a cycle
length that was greater than 20% different from the average
for that patient.
Our methods for measuring average tilling velocities dif-
fer slightly from those reported by Smith et al. (21) in that
only the relatively constant portions of the rapid and slow
tilling phases were used in our study. Thus by not taking
the minimal count point of the curve as the onset of rapid
tilling. we attempted to avoid an error in slope calculation
that might occur if a variable portion of the isovolumic
region of the time-activity curve was included. As a result.
our method yielded more rapid normal velocities than the
average rates reported by Smith et al. (21).
Cardiotoxicity at low dosage. The cumulative doses of
doxorubicin given our patients were relatively low (mean
193 mg/rrr'). Although congestive heart failure develops
more frequently after doxorubicin therapy at cumulative
doses in excess of 550 mg/rn", it has been reported to occur
in 3.5% of patients given 400 mg/rrr ' (32) and even in some
patients given less than 200 mg/m" (11,32). In our study
the lowest total dose of doxorubicin received by a patient
who developed diastolic dysfunction was 166 mg/rn' .
Bristow et al. (18) initially reported on nine patients
treated with doxorubicin without mediastinal radiation who
had mild histopathologic changes in endomyocardial biopsy
specimens when the cumulative dose was less than 300
mg/nr' and on two patients when the dose was less than 200
mg/rrr'. The extent of morphologic change on biopsy was
proportional to the total dose administered throughout a dose
range of 45 to 545 mg/rrr' . Cardiac function changes mea-
sured from systolic time intervals were not encountered at
doses less than 400 mg/rrr'. Bristow et al. (33) later ex-
panded these observations ina study in which left ventricular
function was assessed by echocardiographically derived per-
cent fractional shortening. There was little change in cardiac
function at total doses less than 300 mg/nr' although biopsy
changes were encountered at doses of 100 to 300 mg/rrr '.
Mechanism of diastolic dysfunction. The mechanism
for abnormal left ventricular diastolic tilling induced by
doxorubicin is unknown. It may be that reduction in left
ventricular adenosine triphosphate levels caused by impaired
mitochondrial oxidative function in patients receiving dox-
orubicin (34,35) could inhibit calcium uptake by the sar-
coplasmic reticulum and might account for the abnormalities
in diastolic tilling. The determinants of diastolic function
are multifactorial, and we do not know which factors may
have changed with doxorubicin therapy. Because these stud-
ies were noninvasive, ventricular pressure-volume relations
were not examined. Several investigators (36,37) have pointed
out that increases in heart rate and blood pressure may cause
changes in measures of diastolic left ventricular function,
but there were no significant changes in heart rate and blood
pressure in our patients.
Risk factors for cardiotoxlclty. An increased risk of
clinically apparent cardiotoxicity has been reported in pa-
tients receiving less than 500 mg/rrr' of doxorubicin, if other
cardiotoxic factors, such as combination anticancer therapy
(8,9,32,3 8), previous mediastinal irradiation (5,8,9), hy-
pertension (8) or other heart disease (5) are present.
Age over 70 years has also been cited as an independent
risk factor for development of doxorubicin-associated heart
failure (18). None of our patients were 70 years of age or
older. Although 2 of our 12 patients were hypertensive, we
found no relation between their blood pressures and the
extent of change in diastolic function. None of our patients
had pericardial effusion and none had received radiation
therapy that might impair diastolic performance. Whether
the concomitant administration of cyclophosphamide, vin-
blastine and thio-TEPA with doxorubicin in the present study
had any influence on the diastolic impairment we observed
cannot be evaluated from our data. Thus. the altered dia-
stolic tilling velocities encountered in our patients after dox-
orubicin administration are not explained by age, by con-
current hemodynamic changes or by the effects of other
therapeutic interventions.
Conclusions. In a highly selected group of patients who
received doxorubicin in doses of less than 200 mg/rn", we
found evidence of impaired left ventricular diastolic function
without significant reduction in systolic function. Radio-
nuclide assessment of diastolic as well as systolic function
may be of value in the evaluation of the progressive dete-
rioration of cardiac function associated with doxorubicin
therapy. A prospective study involving serial measurements
at different doses will be required to evaluate the role of
diastolic dysfunction in the early detection of cardiotoxicity.
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